{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T20:33:13Z","timestamp":1765398793834,"version":"3.46.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajoc.2025.102375","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:35:48Z","timestamp":1751423748000},"page":"102375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9049-8567","authenticated-orcid":false,"given":"Laura","family":"Matuszewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-4221","authenticated-orcid":false,"given":"Caitlynn","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Sattarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassef","family":"Chanbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6159-8522","authenticated-orcid":false,"given":"Evan","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2155-8583","authenticated-orcid":false,"given":"Vania","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2025.102375_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"3","key":"10.1016\/j.ajoc.2025.102375_bib2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3892\/mmr.2021.12316","article-title":"Claudin 6: therapeutic prospects for tumours, and mechanisms of expression and regulation","volume":"24","author":"Du","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ajoc.2025.102375_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.783","article-title":"721MO phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors","volume":"35","author":"Konecny","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ajoc.2025.102375_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Therapeut: Off J Assoc Ocul Pharmacol Therapeut"},{"issue":"6","key":"10.1016\/j.ajoc.2025.102375_bib5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/ICU.0000000000001063","article-title":"Ocular toxicities associated with antibody drug conjugates","volume":"35","author":"Marshall","year":"2024","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajoc.2025.102375_bib6","doi-asserted-by":"crossref","unstructured":"Konecny, G.E. et al. First-in-Human phase 1 study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23. Poster Presented at the European Society of Medical Oncology (ESMO) Annual Meeting 2023, October 20-24, Madrid, Spain & Online.","DOI":"10.1016\/j.annonc.2023.09.1935"},{"issue":"12","key":"10.1016\/j.ajoc.2025.102375_bib7","doi-asserted-by":"crossref","first-page":"7258","DOI":"10.1167\/iovs.13-12022","article-title":"Expression and distribution of claudin subtypes in human corneal endothelium","volume":"54","author":"Inagaki","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajoc.2025.102375_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Therapeut"},{"issue":"2","key":"10.1016\/j.ajoc.2025.102375_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40135-024-00322-5","article-title":"Incidence and mitigation of corneal pseudomicrocysts induced by antibody-drug conjugates (ADCs)","volume":"12","author":"Lindgren","year":"2024","journal-title":"Curr Ophthalmol Rep"},{"key":"10.1016\/j.ajoc.2025.102375_bib10","article-title":"Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer","volume":"33","author":"Parikh","year":"2023","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"10.1016\/j.ajoc.2025.102375_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jcjo.2021.02.028","article-title":"Reversible HER2 antibody-drug conjugate-induced ocular toxicity","volume":"57","author":"Sharma","year":"2022","journal-title":"Can J Ophthalmol"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993625001288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993625001288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T20:28:45Z","timestamp":1765398525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993625001288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":11,"alternative-id":["S2451993625001288"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2025.102375","relation":{},"ISSN":["2451-9936"],"issn-type":[{"type":"print","value":"2451-9936"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2025.102375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102375"}}